26
Nov
2024

RMPL Pharma LLP

Exhibitor at CPHI & PMEC India 2024 stand 1A.I04
About Us

RMPL PHARMA LLP is a part of ROYAL group of companies whose inception dates back to 1944.  RMPL PHARMA LLP. is reputed and leading merchant exporters in India of an extensive range of pharmaceuticals (mainly Oncology and other specialized products ) to African, Gulf, European, & South East Asian countries. We are also engaged in wholesale distribution throughout India of specialized pharmaceuticals ( mainly Oncology products ) manufactured by reputed Indian & Multinational companies.
We ...

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • IN
  • 2018
    On CPHI since
  • 1 - 24
    Employees
Company types
Pharmaceutical company
Wholesale/Retail
View company profile
Contact info
  • 022-22004057
  • Office no 2, 1st Floor, Sunbeam Chambers, Opp Liberty Cinema,, Mumbai, India
Show contact info Hide contact info
Event information
CPHI & PMEC India 2024
  • 26 Nov 2024 - 28 Nov 2024
  • India Expo Centre, Greater Noida, Delhi NCR
  • Visit us at stand 1A.I04

Products Featured at CPHI & PMEC India 2024

  • INJ. MELKERAN 50 MG

    Product INJ. MELKERAN 50 MG

    - PALLIATIVE TREATMENT OF MULIPLE MYELOMA.- PALLIATION OF NON - RESECTABLE EPITHELIAL CARCINOMA OF THE OVARY .
  • TAB. MELKERAN 2 MG

    Product TAB. MELKERAN 2 MG

    - PALLIATIVE TREATMENT OF MULIPLE MYELOMA.- PALLIATION OF NON - RESECTABLE EPITHELIAL CARCINOMA OF THE OVARY .
  • INJ.LEUCOVORIN CALCIUM 50 MG

    Product INJ.LEUCOVORIN CALCIUM 50 MG

    - AN ACTIVE METABOLITE OF FOLIC ACID  ( ALSO CALLED  FOLINIC ACID AND CICTROVORUM FACTOR ), WHICH DOSE NOT REQUIRE METABOLISM BY DIHYDROFOLATE REDUCTASE , THE MOLECULAR TARGET OF FOLATE ANTAGONIST- TYPE CHEMOTHERAPEUTIC DRUGS.
  • INJ. HOLOFOS 2 MG

    Product INJ. HOLOFOS 2 MG

    - INDICATED FOR USE IN COMBINATION WITH CERTAIN OTHER APPROVED ANTI NEOPLASTIC AGENT FOR THIRD - LINE CHEMOTHERAPY OF GERMS CELL TESTICULAR CANCER.- IFOSFAMIDE IS COMBINED IS COMBINED WITH MESNA FOR PROPHYLAXIS OF HEMORRHAGIC CYSTITIS.
  • INJ. HOLOFOS 1 GM

    Product INJ. HOLOFOS 1 GM

    - INDICATED FOR USE IN COMBINATION WITH CERTAIN OTHER APPROVED ANTI NEOPLASTIC AGENT FOR THIRD - LINE CHEMOTHERAPY OF GERMS CELL TESTICULAR CANCER.- IFOSFAMIDE IS COMBINED IS COMBINED WITH MESNA FOR PROPHYLAXIS OF HEMORRHAGIC CYSTITIS.